Phase I clinical study of tumor-specific vaccine using novel tumor antigen SCRN1-derived HLA*0201 restricted epitope peptide against advanced gastric cancer

Phase I clinical study of tumor-specific vaccine using novel tumor antigen SCRN1-derived HLA*0201 restricted epitope peptide against advanced gastric cancer - SCRN1 peptide vaccine against gastric cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001013

Enrollment

Registered

2008-02-04

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

peptide vaccine therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance status 0-2 HLA-A20201 Refractory to 5FU containing chemotherapeutic regimen

Exclusion criteria

Exclusion criteria: pregnancy uncontroled infection uncontroled cerebral metastasis etc.

Design outcomes

Primary

Measure	Time frame
Assessment of safety and antitumor immune responses	—

Secondary

Measure	Time frame
Clinical efficacy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026